These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 7998098)

  • 21. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation.
    Holler E; Kolb HJ; Hintermeier-Knabe R; Mittermüller J; Thierfelder S; Kaul M; Wilmanns W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1234-6. PubMed ID: 8442099
    [No Abstract]   [Full Text] [Related]  

  • 22. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10.
    Donckier V; Flament V; Gérard C; Abramowicz D; Vandenabeele P; Wissing M; Delvaux A; Fiers W; Leo O; Velu T
    Transplantation; 1994 May; 57(10):1436-9. PubMed ID: 8197603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
    Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
    Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
    [No Abstract]   [Full Text] [Related]  

  • 24. Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory.
    Skea DL; Barber BH
    J Immunol; 1993 Oct; 151(7):3557-68. PubMed ID: 8376792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients.
    Leimenstoll G; Zabel P; Schroeder P; Schlaak M; Niedermayer W
    Transplant Proc; 1993 Feb; 25(1 Pt 1):561-3. PubMed ID: 8438414
    [No Abstract]   [Full Text] [Related]  

  • 26. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [T lymphocyte activation induced in vivo in different strains of mice after injection of anti-CD3 antibodies: prevention by an anti- TNF antibody].
    Ferran C
    Nephrologie; 1993; 14(1):23-4. PubMed ID: 8502345
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic in vivo use of the A1-CD3 monoclonal antibody.
    Hilgert I; Franĕk F; Stefanová I; Kaslík J; Jirka J; Kristofová H; Rossmann P; Soucek J; Horejsi V
    Transplantation; 1993 Feb; 55(2):435-8. PubMed ID: 8434399
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3.
    Agarwal RK; Ostaszewski ML; Feld LG; Springate JE; Moxey-Mims MM; O'Neil KM
    Transplant Proc; 1993 Apr; 25(2):2143-4. PubMed ID: 8470295
    [No Abstract]   [Full Text] [Related]  

  • 31. Current advantage of FK 506 in cadaveric kidney transplantation.
    Ciancio G; Rosen A; Loreto-Grand B; Burke G; Siquijor A; Luque C; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207
    [No Abstract]   [Full Text] [Related]  

  • 32. Isotype regulation: IgG and IgA.
    Int Rev Immunol; 1987 Jan; 2(2):117-240. PubMed ID: 3507453
    [No Abstract]   [Full Text] [Related]  

  • 33. A rat anti-mouse CD3 monoclonal antibody induces long-term skin allograft survival without inducing side effects.
    Vossen AC; Tibbe GJ; van Oudenaren A; Vredendaal AE; Benner R; Savelkoul HF
    Transplant Proc; 1994 Dec; 26(6):3157-8. PubMed ID: 7998101
    [No Abstract]   [Full Text] [Related]  

  • 34. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
    Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
    J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
    [No Abstract]   [Full Text] [Related]  

  • 35. Involvement of tumor necrosis factor in development of anti-CD3 monoclonal antibody induced pulmonary edema.
    Nakajima F; Nakamura H; Stenzel KH; Suthanthiran M
    Transplant Proc; 1994 Aug; 26(4):1939-40. PubMed ID: 8066628
    [No Abstract]   [Full Text] [Related]  

  • 36. Isotype selection for antibody-based cancer therapy.
    Vukovic N; van Elsas A; Verbeek JS; Zaiss DMW
    Clin Exp Immunol; 2021 Mar; 203(3):351-365. PubMed ID: 33155272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity of IgA anti-CD3 isotype switch variant in vivo.
    ten Berge IJ; Parlevliet KJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
    Transplant Proc; 1994 Dec; 26(6):3150. PubMed ID: 7998098
    [No Abstract]   [Full Text] [Related]  

  • 38. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
    Parlevliet KJ; ten Berge IJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
    J Clin Invest; 1994 Jun; 93(6):2519-25. PubMed ID: 8200988
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.